Pharmacist Guidelines for Managing Reflux and GORD
A series of clinical practice guidelines, published by the Australasian College of Pharmacy and aligned with Therapeutic Guidelines, outline a structured framework for community pharmacists to assess and manage patients presenting with symptoms of gastro-oesophageal reflux (GOR) and gastro-oesophageal reflux disease (GORD). The guidelines integrate non-pharmacological strategies with a stepwise approach to pharmacological treatment, reflecting an expanded scope of practice for pharmacists in some Australian jurisdictions.
Condition Overview and Prevalence
Gastro-oesophageal reflux (GOR) is described as a common physiological event involving the backward flow of stomach contents into the oesophagus. Gastro-oesophageal reflux disease (GORD) is diagnosed when reflux causes significant symptoms or potential mucosal damage.
A global meta-analysis cited in the guidelines suggests a pooled GORD prevalence of approximately 13.9%, while the prevalence of related symptoms in adults is reported to vary widely from 2.5% to 52.1% depending on definition and location.
Pharmacist Role and Initial Assessment
The guidelines state that community pharmacists are often the first healthcare providers consulted for symptoms such as heartburn and regurgitation. Management begins with structured patient history-taking to assess symptom frequency, severity, and pattern. This assessment is used to guide treatment and to identify "alarm" symptoms that necessitate medical referral.
These alarm symptoms include:
- Difficulty swallowing (dysphagia)
- Unintended weight loss
- Cardiac-like chest pain
- Severe abdominal pain
- Sudden onset of symptoms in a person aged 65 years or older
- Haematemesis or melaena (blood in vomit or stool)
A poor response to a short course of over-the-counter acid-suppressive therapy is also noted as a reason for medical consultation.
Management Framework
Management is based on symptom frequency and severity, combining lifestyle modification with pharmacological treatment.
Non-Pharmacological Strategies
The guidelines highlight several lifestyle modifications supported by clinical evidence:
- Weight reduction for individuals with a high body mass index.
- Avoidance or reduction of tobacco smoking.
- Elevating the bedhead by 15–20 cm for nocturnal symptoms.
Other commonly recommended strategies include eating smaller meals, avoiding meals 2–3 hours before bedtime, and managing dietary triggers.
Pharmacological Treatment Options
Four main over-the-counter (OTC) therapeutic classes are available in Australia for initial management:
- Antacids: Provide rapid, temporary symptom relief by neutralising stomach acid, with effects lasting from 20 minutes to 3 hours.
- Alginates/Antacid-Alginate Combinations: Form a physical barrier or "raft" on stomach contents to reduce reflux, providing symptom relief for several hours. A meta-analysis cited in one source indicates alginate-based products increase the odds of GORD symptom resolution compared to placebo or antacids alone.
- Histamine-2 Receptor Antagonists (H₂RAs): Suppress gastric acid secretion, with an onset of about 60 minutes and effects lasting 4 to 12 hours. They are suggested for mild or intermittent symptoms.
- Proton Pump Inhibitors (PPIs): Described as the most potent OTC acid suppressants. They irreversibly inhibit the proton pump, with effects lasting 15 to 24 hours after 1-3 days of treatment. OTC PPIs are typically taken once daily.
Stepwise Treatment Recommendations
The Therapeutic Guidelines (TG) recommend a tailored approach:
For mild, intermittent symptoms (1–2 episodes weekly), initial options include antacid-alginate combinations, combined magnesium-aluminium antacids, H₂RAs, or a standard-dose PPI.
For frequent or severe GORD symptoms, an initial 4–8 week course of a standard-dose PPI is recommended, followed by step-down maintenance therapy (e.g., to an H₂RA or on-demand PPI).
Antacid-alginate therapy is noted for providing rapid relief and can be used adjunctively during PPI initiation or step-down to manage breakthrough symptoms.
Expanded Scope of Practice
The guidelines reference an expanded scope of practice for pharmacists in some Australian jurisdictions, notably Queensland and New South Wales. Since July 2025, pharmacists who complete additional training can prescribe medicines for specified acute conditions, including GOR and GORD, in accordance with state-based clinical practice frameworks.
This expanded scope allows for extended initial PPI treatment periods beyond standard OTC course limits and, in Queensland, access to Schedule 4 H₂RAs. The state frameworks emphasize that this prescribing should be integrated with advice on non-pharmacological management.
Case Example and Follow-Up
Multiple sources include a consistent case scenario of a 52-year-old patient presenting with reflux symptoms. The demonstrated management involves lifestyle counselling, a 14-day OTC PPI course, and an antacid-alginate for breakthrough symptoms.
The guidelines advise pharmacists to schedule a follow-up review with patients after 2–4 weeks to assess progress and consider step-down therapy.
Guideline Accreditation
The clinical content is associated with a Continuing Professional Development (CPD) activity accredited by the Pharmaceutical Society of Australia, carrying accreditation number PSAAP2605TG with an expiry date of 31 March 2028.